In many ways, genetic diseases, such as cystic fibrosis (CF), are ideal candidates for molecular therapy. However, several obstacles, including inefficient delivery/uptake and the potential toxicity of presently available vectors, remain to prevent widespread clinical use. The Molecular Core in the context of the MTCC will serve the gene transfer community at UNC-CH in two ways. First, it will provide access to newly developed mouse model whose airways mimic the mucus filled human CF lung. These mice, which were developed by airway-specific overexpression of the beta subunit of the mouse epithelial sodium channel, exhibit many of the same characteristics of a human CF, including hyperabsorption of Na+, reduced periciliary liquid, decreased mucociliary clearance, and mucus accumulation and plugging. As such, they serve as an excellent model to evaluate delivery methods and vectors in the context of CF-like disease. The Molecular Core will breed and maintain these mice on a variety of backgrounds, will provide experimental animals to investigators, and will expand upon this model by modifying the promoter elements used in the transgenic lines. Secondly, the Molecular Core will provide toxicogenomic services. This will be accomplished by utilizing Affymetrix GeneChip arrays for RNA expression analysis. Microarrays will be used to identify gene expression changes within cells after treatment with various vectors. This data will be used to evaluate the potential toxicity of the vector in a clinical setting. Specifically, the Molecular Core will provide investigators with expertise on experimental design, RNA isolation services, the GeneChip arrays needed to conduct the experiment, data analysis/interpretation services, and access to validation via quantitative real-time PCR (Roche LightCycler instrumentation and expertise). In addition, the Molecular Core will maintain a database that will allow new experiments to be efficiently compared with data from past experiments. This mechanism should facilitate efficient evaluation of new vector modifications as they relate to the potential safety/toxicity issues. By providing a relevant model for CF airways disease and an efficient mechanism to evaluate the potential toxicity of new vectors, the efforts of the Molecular Core should reduce the time to achieve molecular therapy for diseases such as CF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
1P30DK065988-01
Application #
6774594
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (O1))
Project Start
2003-09-30
Project End
2008-09-29
Budget Start
2003-09-30
Budget End
2005-03-31
Support Year
1
Fiscal Year
2004
Total Cost
$145,787
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kim, Christine Seulki; Ahmad, Saira; Wu, Tongde et al. (2018) SPLUNC1 is an allosteric modulator of the epithelial sodium channel. FASEB J 32:2478-2491
Polineni, Deepika; Dang, Hong; Gallins, Paul J et al. (2018) Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity. Am J Respir Crit Care Med 197:79-93
Abdullah, Lubna H; Coakley, Raymond; Webster, Megan J et al. (2018) Mucin Production and Hydration Responses to Mucopurulent Materials in Normal versus Cystic Fibrosis Airway Epithelia. Am J Respir Crit Care Med 197:481-491
Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304
Gentzsch, Martina; Mall, Marcus A (2018) Ion Channel Modulators in Cystic Fibrosis. Chest 154:383-393
Terryah, Shawn T; Fellner, Robert C; Ahmad, Saira et al. (2018) Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 314:L192-L205
Gillen, Austin E; Yang, Rui; Cotton, Calvin U et al. (2018) Molecular characterization of gene regulatory networks in primary human tracheal and bronchial epithelial cells. J Cyst Fibros 17:444-453
Muhlebach, Marianne S; Zorn, Bryan T; Esther, Charles R et al. (2018) Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. PLoS Pathog 14:e1006798
Cholon, Deborah M; Gentzsch, Martina (2018) Recent progress in translational cystic fibrosis research using precision medicine strategies. J Cyst Fibros 17:S52-S60
Porrello, Alessandro; Leslie, Patrick L; Harrison, Emily B et al. (2018) Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. Nat Commun 9:1988

Showing the most recent 10 out of 133 publications